TME Pharma receives US FDA Fast Track designation for lead asset NOX-A12 in brain cancer
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
Clinical trial protocol approved in the US to initiate Phase 2 study with NOX-A12 in glioblastoma providing a clear road…
Substantially improved survival and progression-free survival under NOX-A12 treatment combination compared to matched st…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
83% of glioblastoma patients remain alive after 15 months on study, unchanged from the 14-month survival update 15-month…
Abstract highlights biomarker with ability to predict clinical responses of glioblastoma patients to NOX-A12-based thera…
83% of glioblastoma patients remain alive after 14 months on study, a percentage well above what is expected for the enr…
. Selection for presentation by ASCO highlights the strength of TME Pharma’s science and the importance of results eme…
. Clinical benefit to date compares favorably with expected survival in this difficult to treat population Median over…
With a 10-month median follow-up to date 5 of 6 patients remain alive Follow-up continues since median overall survival…